Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Nausea 12Vomiting 11Neoplasms 7Hematologic Neoplasms 5Anorexia 4Cachexia 3Breast Neoplasms 3Weight Loss 2Stomach Neoplasms 2Advanced Cancer 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Sedentary Behavior 1Prosthesis Failure 1Postoperative Nausea and Vomiting 1Pain 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Muscular Atrophy 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1Gynecologic Cancer 1Esophageal Neoplasms 1

Interventions

ziprasidone 1lorlatinib 1Urine Specimen Collection 1Tamoxifen 1Olanzapine 1Lysine Acetyltransferase 5 1Goserelin 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hyperlipidemias × Olanzapine × Clear all
NCT00910988 2018-07-18

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Washington University School of Medicine

Phase NA Completed
46 enrolled 38 charts
Endocrine

Hyperglycemia, Hyperlipidemias, Insulin Resistance, Multiple Endocrine Neoplasia Type 1, Sedentary Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡